Dare Bioscience Inc (DARE) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal...

Form EFFECT - Notice of Effectiveness

Form 424B5 - Prospectus [Rule 424(b)(5)]

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving...

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in...

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase...

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available...

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s...

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the...